deoxycytidine and Ovarian Neoplasms

deoxycytidine has been researched along with Ovarian Neoplasms in 433 studies

Research

Studies (433)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's46 (10.62)18.2507
2000's187 (43.19)29.6817
2010's171 (39.49)24.3611
2020's29 (6.70)2.80

Authors

AuthorsStudies
Cheng, SC; Chowdhury, D; Curtis, J; D'Andrea, AD; da Costa, AABA; Färkkilä, A; Gulhan, D; Hendrickson, AEW; Kochupurakkal, B; Kohn, EC; Kolin, DL; Konstantinopoulos, PA; Lee, EK; Liu, JF; Matulonis, UA; Polak, M; Shapiro, GI; Stover, EH; Tayob, N1
Mo, DC; Ren, T1
Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T1
Ahmad, M; Alharbi, H; Aloahd, MS; Alrashed, MM; Alshehry, AS1
Anjum, MM; Bhattacharya, S; Patel, KK1
Al-Mutairi, AA; Alkhatib, MH1
Arakawa, A; Goto, M; Hori, K; Ito, K; Kaneda, M; Kawabata, A; Kaya, R; Kondo, E; Motohashi, T; Nagasawa, T; Nakagawa, M; Nasu, H; Nishio, S; Park, J; Shimokawa, M; Suzuki, J; Tashima, L; Tsubamoto, H; Yamada, K; Yanagida, S1
Azzouqa, AG; Colon-Otero, G; Kase, AM; Kochuveettil, S1
Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I1
Feng, W; Tang, Z; Wang, Q; Yang, Y1
Berg, T; Nøttrup, TJ; Roed, H1
Kato, T; Kiyokawa, T; Kohno, T; Kuroda, T; Ogiwara, H; Okamoto, A; Sasaki, M; Sudo, K; Takahashi, K; Tamura, K; Yoshida, H1
Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G1
Bell, R; Bell-McGuinn, K; Buderath, P; Campbell, R; Farrington, DL; Fiorica, J; Golden, L; Hamilton, A; Heitz, F; Lee, CM; Moore, KN; Pitou, C; Powell, M; Sehouli, J; Teneriello, M; Vergote, I; Wenham, RM; Zhang, W1
Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B1
Kohno, T; Kuroda, T1
Jimi, T; Kitai, M; Kogiku, A; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Suzuki, K; Yamaguchi, S; Yamamoto, K1
Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M1
Hada, T; Ishibashi, H; Iwahashi, H; Kakimoto, S; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Suminokura, J; Takano, M1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z1
Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW1
Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS1
Fujiwara, H; Koyanagi, T; Machida, S; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Tamura, K; Taneichi, A; Yoshiba, T1
Kato, K; Matsuoka, A; Nishikimi, K; Otsuka, S; Shozu, M; Takahashi, Y; Tate, S1
Blagden, SP; Nicum, S1
Bowering, V; Bruce, JP; Cabanero, M; Chen, E; Cristea, MC; Dhani, NC; Ellard, SL; Fleming, GF; Garg, S; Jenkins, S; Jones, GN; Karakasis, K; Kunos, CA; Lheureux, S; Mantia-Smaldone, G; Olawaiye, AB; Oza, AM; Pugh, TJ; Rath, P; Rodriguez-Canales, J; Stockley, T; Tan, Q; Tracy, M; Udagani, S; Wahner Hendrickson, AE; Wang, L; Weberpals, JI; Welch, S1
Eleraky, NE; Hasan, OA; Omar, MM; Zaki, RM1
Di Benedetto, L; Gozzi, E; Lazzeroni, R; Pietranera, M; Raimondi, FM; Raimondi, L; Rossi, L; Spinelli, GP1
Killock, D1
Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D1
Goto, M; Hori, K; Ito, K; Nakagawa, M; Ono, H; Onoue, M; Shimoji, K; Shiomi, M; Suzuki, J; Tashima, L; Uragami, K; Yamashita, M; Yoshioka, E1
Agopsowicz, K; Burlot, C; Cardinal, O; Craig, M; Crosley, P; Farkkila, A; Fu, Y; Heikinheimo, M; Hitt, MM; Jenner, AL; Pihlajoki, M; Potts, KG1
Cass, I; Kamrava, M; Karlan, B; Kim, S; Li, A; Rimel, BJ; Rogatko, A; Walsh, CS1
Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Galluzzi, L; Hassan, HIB; Hein, A; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Madry, R; Mallmann, P; Markowska, J; Melichar, B; Minar, L; Pecen, L; Pluta, M; Rob, L; Spacek, J; Spisek, R; Streb, J; Valha, P; Wimberger, P1
Ariyoshi, K; Matsushita, S; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Shimokawa, M; Yamaguchi, S1
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ1
Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P1
Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG1
Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U1
Gurunathan, S; Peng, QL; Yuan, YG1
Bonetti, A; Giuliani, J1
Bruckner, HW; Gurell, D; Hirschfeld, A1
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H1
Farley, J; Kundranda, MN; Markman, M; Niu, J1
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T1
Chan, MW; Chang, CC; Chen, HJ; Chen, LY; Huang, RL; Lai, HC; Liew, PL; Su, PH; Wang, YC; Weng, YC1
Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C1
Chen, X; Shen, N; Tang, Z; Wang, G; Yang, S; Zhang, D1
Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ1
Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F1
Garcia-Cremades, M; Iversen, PW; Pitou, C; Troconiz, IF1
Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Kouroussis, C; Polyzos, A; Syrios, J; Vardakis, N1
Hu, Y; Li, C; Xie, Y; Zeng, Q1
Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B1
Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH1
Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S1
du Bois, A; Harter, P; Heitz, F; Kurzeder, C; Lubbe, D; Pfisterer, J; Plante, M; Vergote, I1
Dohrmann, T; Izbicki, JR; Jaenicke, F; Kutup, A; Mahner, S; Müller, V; Vashist, YK1
Altevogt, P; Bretz, NP; Fogel, M; Hazin, J; Herr, I; Keller, S; Moldenhauer, G; Perne, C; Salnikov, AV; Schlange, T1
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE1
Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, HJ1
Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M1
Morishita, F; Okazawa, H; Orisaka, M; Tsuyoshi, H; Yoshida, Y1
Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M1
Beijnen, JH; Huitema, AD; Leijen, S; Schellens, JH; van Werkhoven, E; Veltkamp, SA1
Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM1
Adam, J; Pinilla-Dominguez, P; Richardson, J; Robertson, J1
Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T1
Cheney, DL; Ghandehari, H; Kopeček, J; Larson, N; Ray, A; Yang, J1
Contreras-Steyls, M; Estrada, D; Gallego, E; Herrera, E; López-Navarro, N; Moyano, B1
Chen, WJ; Xiong, JP; Yuan, SF; Zhang, LP; Zheng, WE; Zhu, LJ1
Ariyoshi, K; Eto, T; Okadome, M; Saito, T; Shimamoto, K; Tomita, Y1
Arena, MG; Barba, M; Corrado, G; Di Lauro, L; Giannarelli, D; Mariani, L; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, F; Tomao, S; Vici, P; Vincenzoni, C; Vizza, E1
Bai, J; Fu, S; Guan, R; Huang, Y; Ji, W; Jin, Y; Meng, X; Quan, C; Sun, D; Sun, W; Yu, L; Yu, Y; Zhang, C; Zhao, Y; Zhu, J1
Abe, T; Fuga, M; Hasegawa, Y; Irie, K; Kawamura, D; Tanaka, T; Tochigi, S; Yanagisawa, T1
Asna, N; Grisaru, D; Inbar, M; Matcejevsky, D; Safra, T; Shpigel, S; Veizman, A1
Momeni, M; Veras, L; Zakashansky, K1
Clements, D; Dielschneider, R; Gujar, SA; Helson, E; Lee, PW; Marcato, P1
Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kikuchi, A; Kobayashi, H; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H1
Sinha, G1
Aghajanian, C; Blank, S; Goff, B; Husain, A; Nycum, LR; Wang, Y1
Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y1
Ashihara, K; Fujiwara, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Takai, M; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S1
Callahan, MJ; Cobb, B; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R; Sutton, G; Zanagnolo, V1
Cheung, SS; Hasman, D; Tai, J1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q1
Chanpanitkitchot, S; Khunnarong, J; Pataradool, K; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T1
Kopeček, J; Sima, M; Yang, J; Zhang, R; Zhou, Y1
Bryant, C; Massey, AJ; Rawlinson, R1
Blanco-González, E; Espina, M; Iglesias, T; Montes-Bayón, M; Sierra, LM1
Liu, LH; Liu, YH; Xu, L; Yang, H1
Bosetti, R; Ferrandina, G; Marneffe, W; Scambia, G; Vereeck, L1
Byun, JH; Hong, SH; Jung, KH; Kim, HG; Kim, HY; Kim, KH; Lee, HJ; Lee, NR; Lee, S; Lee, SC; Park, KH; Rha, SY; Woo, IS; Yun, J1
Bhutia, YD; Cummins, S; Dhar, S; Govindarajan, R; Hooks, SB; Hung, SW; Marrache, S; Mody, H1
Barton, S; Edwards, SJ; Thurgar, E; Trevor, N1
Matsumoto, K; Onda, T; Yaegashi, N1
Ding, T; Liu, XH; Lv, QY; Song, J; Wang, SH; Wang, Y; Wei, MH; Wu, MD; Yang, QH; Zhou, J; Zhou, YF1
Li, Y; Shang, YM; Yang, Y; Zheng, H1
Alfredsson, J; Björklund, U; Bykov, VJ; Byström, S; Fransson, Å; Gullbo, J; Hallberg, A; Mohell, N; Uustalu, M; Wiman, KG1
Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C1
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T1
Asami, Y; Iiba, M; Kitagawa, R; Kondo, K; Sato, N; Sugita, M; Tadauchi, K; Tsunoda, H; Uenoyama, A1
Aghajanian, C; Blank, SV; Goff, B; Husain, A; Nycum, LR; Wang, YV1
Daemen, TA; Dijkgraaf, EM; Goedemans, R; Kroep, JR; Melief, CJ; Nijman, HW; Reyners, AK; Santegoets, SJ; Smit, VT; van der Burg, SH; van der Hoeven, JJ; van Erkel, AR; van Poelgeest, MI; Welters, MJ1
Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB1
Inatsu, H; Kondo, Y; Murata, T; Nyomura, S; Takahashi, N; Tokunaga, M; Tomita, K1
Bourade, V; Chen, E; Doyle, L; Goel, R; Halford, R; Jonker, D; Keller, D; Laurie, SA; Lheureux, S; Oza, AM; Siu, LL; Wang, L1
Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA1
Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H1
Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A1
du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A1
Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T1
Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A1
Ben Shem, E; Ben Zvi, M; Levy, T; Menczer, J; Peled, O; Schreiber, L; Vaknine, H1
Adams, DJ; Bansal, V; Kota, R; Kulhari, H; Pooja, D; Reddy, TS; Shukla, R; Sistla, R; Tabor, RF1
Brody, JR; Daum, GS; DuHadaway, JB; Dunton, CJ; Furuuchi, N; Huang, YH; Jimbo, M; Leiby, BE; Peng, W; Pirritano, A; Sawicki, JA1
Aglietta, M; Calogero, R; De Simone, M; Di Renzo, MF; Erriquez, J; Katsaros, D; Mittica, G; Olivero, M; Ponzone, R; Scalzo, MS; Vaira, M; Valabrega, G1
Abramian, A; Arden, JM; Ayub, TH; Doeser, A; Hecking, T; Hoeller, T; Kaiser, C; Keyver-Paik, MD; Kuhn, W; Lüders, C; Thiesler, T1
Enas, NH; Friberg, LE; Gueorguieva, I; Zecchin, C1
Bastiere-Truchot, L; Berton-Rigaud, D; Colombo, N; Del Campo, JM; du Bois, A; Gadducci, A; García, Y; González-Martín, A; Kiermaier, A; Kurzeder, C; Mahner, S; Marmé, F; Martin, N; Ortega, E; Ottevanger, P; Pautier, P; Rau, J; Selle, F1
Almorsy, W; Elshebeiny, M1
Chan, C; Duan, X; Han, W; Lin, W; Poon, C1
Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A1
Fujiwara, H; Machida, S; Matsubara, S; Morisawa, H; Nagashima, T; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Taneichi, A1
Du, X; Li, X; Liu, N; Sheng, X; Wang, F; Yu, H1
Chao, Y; Hou, MC; Lan, KH; Lee, SD; Lee, WP; Li, CP; Lin, HC1
Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R1
Fang, Y; Kopeček, J; Li, Y; Pan, H; Yang, J; Zhang, L; Zhang, R1
Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Nishimura, J; Ohara, N; Satoh, T; Takahashi, H; Yamamoto, H1
Blackwood, E; Cao, Y; Evangelista, M; Klijn, C; Lee, HJ; Pham, V; Settleman, J; Stokoe, D; Wilson, C1
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC1
Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D1
Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG1
Goodman, A; Ko, E; Lee, S1
Eisenkop, SM; McAlpine, JN; Spirtos, NM1
Etoh, T; Hoshiai, H; Koike, E; Nakai, H; Watanabe, Y1
Backes, FJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG; Zanagnolo, V1
Aghajanian, CA; Fury, M; Gerst, S; Goss, TL; Hensley, ML; Konner, J; Larkin, J; Orlando, M; Sabbatini, P; Tai, DF1
Adrover Cebrian, E; Alonso Carrion, L; Arcusa Lanza, A; Bover Barcelo, I; Calvo Garcia, E; Casado Herraez, A; Churruca Galaz, C; Fabregat i Mayol, X; Gonzalez Martin, A; Herrero Ibañez, A; Mellado, B; Ojeda Gonzalez, B; Poveda Velasco, A; Rubio Perez, MJ1
Alberola Candel, V; Esteban González, E; Gasent Blesa, JM; Martín Algarra, S; Provencio Pulla, M1
Agostini, C; Aleba, A; Cretin, J; Dohollou, N; Ferrero, JM; Fric, D; Geay, JF; Gouttebel, MC; Haddad-Guichard, Z; Hardy-Bessard, AC; Lévy, E; Orfeuvre, H; Paraiso, D; Provencal, J; Pujade-Lauraine, E; Ray-Coquard, I; Salvat, J; Weber, B1
Hoskins, PJ1
Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL1
Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y1
Beneduce, G; Breda, E; Di Maio, M; Forestieri, V; Gallo, C; Gebbia, V; Greggi, S; Lauria, R; Losito, S; Morabito, A; Pignata, S; Pisano, C; Scalone, S; Scaltriti, L; Sorio, R; Zagonel, V1
Brown, JV; Goldstein, BH; John, CR; Markman, M; Micha, JP; Rettenmaier, MA1
Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R1
Frumovitz, M; Han, LY; Rashid, A; Ricks, AM1
Adachi, S; Akiyama, M; Fujita, H; Hosokawa, K; Itani, Y; Ito, K; Tabata, T; Takeuchi, S; Tsubamoto, H1
Chovanec, J; Dorr, A; Habetinek, V; Helpianska, L; Horvathova, D; Jancokova, I; Koza, I; Kroslakova, D; Lalabova, R; Laluha, A; Magdin, D; Malec, V; Minarik, T; Packan, T; Rakicka, G; Sevcik, L; Spacek, J; Stresko, M; Sufliarsky, J; Svetlovska, D; Tkacova, V1
de la Peña, FA; Garcia-Martinez, E; Vicente, E; Zafra, M1
Emerich, J; Gołka, KA; Kobierski, J; Milczek, T1
Bernstein Molho, R; Grisaru, D; Inbar, M; Levy, T; Menzcher, J; Safra, T1
Alexandrescu, DT; Dasanu, CA; Herzog, TJ1
Felekouras, E; Giannakopoulos, K; Giannopoulos, A; Gogas, H; Karatzas, T; Lagadas, A; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N; Tsigris, C1
Danesi, R; Del Tacca, M; Ferlini, C; Ferrandina, G; Mey, V; Nannizzi, S; Petrillo, M; Ricciardi, S; Scambia, G1
Bourgeois, H; Chevalier-Place, A; Delva, R; Guardiola, E; Henry-Amar, M; Joly, F; Mayer, F; Pautier, P; Petit, T; Sevin, E1
Alvarez, RD; Gallion, HH; García, AA; Kilgore, LC; Lucci, J; Mannel, R; Numnum, TM; Orlando, M; Tai, DF; Zou, SX1
Amler, LC; Dizon, DS; Glenn, D; Gold, MA; Januario, T; Kelsey, S; Lin, CY; Makhija, S; Matulonis, U; Ng, K; Paton, V; Sliwkowski, MX; Strauss, A; Ueland, FR1
Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R1
Daniele, A; Ferrero, A; Fuso, L; Logrippo, V; Perotto, S; Spanu, PG; Zola, P1
Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C1
Besova, NS; Borisov, VI; Bychkov, MB; Chitiia, LV; Filatova, LV; Garin, AM; Gershanovich, ML; Gorbunova, VA; Gurov, SN; Makhnova, EV; Nebol'sin, VE; Raĭkhlin, NT; Sitdikova, SM; Topchieva, SV; Treshchalina, EM; Verebnikova, NV1
Amarantidis, K; Chamalidou, E; Chatzaki, E; Dimopoulos, P; Kakolyris, S; Karakitsos, P; Neanidis, K; Pitsiava, D; Tentes, A; Xenidis, N1
Agarwal, R; Carty, K; Gabra, H; Gore, ME; Gourley, C; Kaye, SB; Parkin, DE; Paul, J; Perren, TJ; Reed, N; Rustin, GJ1
Athanasas, G; Economopoulos, T; Koumarianou, A; Macheras, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Pliarchopoulou, K; Psyrri, A; Xiros, N1
Bifulco, G; Carlomagno, C; De Placido, S; Insabato, L; Lauria, R1
Bertelsen, K; Christensen, RD; Keldsen, N; Lindegaard, JC; Lund, B; Mellemgaard, A; Mirza, MR1
Arcuri, C; Arisi, E; Caffo, O; Caldara, A; Ferro, A; Galligioni, E; Griso, C; Murgia, V; Scalone, S; Sorio, R1
Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M1
Gabra, H; Hartley, JA; James, LE; Jayson, GC; Jitlal, M; Ledermann, JA; Rustin, GJ; Spanswick, VJ1
Avall-Lundqvist, E; Burges, A; du Bois, A; Gropp, M; Hardy-Bessard, AC; Harter, P; Herrstedt, J; Huober, J; Jackisch, C; Jelic, S; Joly, F; Kristensen, G; Kurzeder, C; Müller, HH; Pfisterer, J; Pujade-Lauraine, E; Sehouli, J; Staehle, A; Weber, B; Wimberger, P1
Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J1
Lin, YG; Matsuo, K; Roman, LD; Sood, AK1
Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ1
Aneiros-Fernandez, J; Arias-Santiago, S; Husein-ElAhmed, H; Naranjo-Sintes, R1
Grendys, EC; Holloway, RW; Lefebvre, P; McMeekin, S; Vekeman, F1
Gupta, P; Khanna, AK; Khanna, R; Singh, S1
Jang, JS; Kim, HJ; Kim, KH; Kim, MC; Kim, SH; Kwon, HC; Kwon, KA; Lee, HS; Lee, S; Oh, SY1
Benz, M; Czernin, J; Fueger, B; Phelps, ME; Radu, CG; Satyamurthy, N; Schiepers, C; Schwarzenberg, J; Tran, AQ; Witte, ON1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Hilpert, F; Jonat, W; Kuemper, C; Mundhenke, C; Schaefer, F; Strauss, A1
Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D1
Blomfield, P; Bohmer, R; Chan, WS; McIntosh, R1
Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW1
Berros, JP; Blay, P; Crespo, G; Esteban, E; Fernández, Y; Fonseca, PJ; Fra, J; Lacave, AJ; Losa, R; Luque, M; Muriel, C; Sanmamed, M; Sierra, M; Villanueva, N1
Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A1
Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C1
Chen, DY; Qi, Q; Zhao, WY1
Aoki, D; Bartholomeusz, C; Ishihara, H; Itamochi, H; Kigawa, J; Suzuki, N; Terakawa, N; Ueno, NT; Walker, CL; Yoshida, T1
Brüning, A; Burger, P; Gingelmaier, A; Mylonas, I1
Bruzzone, M; Centurioni, MG; Cosso, M; Cristoforoni, P; Ferrarini, M; Giannelli, F; Giglione, P; Gualco, M; Merlo, DF; Miglietta, L1
Armstrong, DK; Bristow, RE; Diaz-Montes, TP; Giuntoli, RL1
Hatakeyama, K; Iiai, T; Kameyama, H; Nogami, H; Saitou, K; Umezu, H; Yagi, Y1
Lagerstedt, E; Mäenpää, J; Seppänen, J; Staff, S1
Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Morrison, J; Nicum, S1
Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L1
Camoriano, JK; Colon-Otero, G; Erlichman, C; Glaser, G; Haluska, P; Hendrickson, AE; Ivy, SP; Karnitz, LM; Kaufmann, SH; Oberg, AL; Peethambaram, PP1
Eichler, K; Gruber-Rouh, T; Lehnert, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S1
Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H1
Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K1
Orlova, RV; Protasova, AE1
Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S1
Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C1
Belmont, LD; Fairbrother, WJ; Peale, FV; Tan, N; Wong, M; Yue, P; Zha, J1
Bookman, MA4
Thigpen, T3
Facio, G; Garcia, AA; Muderspach, L; Pham, H; Roman, L; Yessaian, A1
Cao, K; Dai, J; Li, L; Li, MY; Lin, C; Nie, CL; Wang, BN; Yang, J; Yang, Y; Yuan, Z; Zhang, J1
Cheewakriangkrai, C; Manopunya, M; Suprasert, P1
Furuya, K; Goto, T; Kato, M; Miyamoto, M; Sasaki, N; Takano, M1
Apte, SM; Bicaku, E; Bou Zgheib, N; Chen, DT; Chon, HS; Cubitt, CL; Gonzalez-Bosquet, J; Hakam, A; Judson, PL; Lancaster, JM; Marchion, DC; Sawah, EA; Stickles, XB; Wenham, RM; Xiong, Y1
Arsenijevic, L; Atanackovic, J; Jeftovic, M; Jeremic, K; Stefanovic, A; Stojnic, J; Zecevic, N1
Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L1
Basile, S; Bellati, F; Benedetti-Panici, P; Di Donato, V; Donfrancesco, C; Graziano, M; Marchetti, C; Palaia, I; Pernice, M; Perniola, G; Tomao, F1
Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, R1
Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL1
Enomoto, T; Fujita, M; Hiramatsu, K; Kimura, T; Kiyohara, Y; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K1
Bagnobianchi, A; Bingham, JP; Craddock, C; Hartley, JA; Hochhauser, D; Kiakos, K; Ledermann, JA; Lowe, HL; Newton, C; Spanswick, VJ1
Katsumata, N; Maejima, A1
Kitao, A; Matsumoto, K1
Chandran, S; Chennazhi, K; Lakshmanan, VK; Nair, SV; Pavithran, K; Praveen, G; Snima, KS1
Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK1
Goto, T; Ikeda, Y; Kikuchi, Y; Kita, T; Kouta, H; Kudoh, K; Oda, K; Sasaki, N; Takano, M1
Cruickshank, S; Delmore, JE; diZerega, GS; Drummond, L; Peterson, KJ; Pham, H; Reed, E; Rodgers, KE; Schwartz, BM1
Allott, CP; Boxall, FE; Kelland, LR; Rogers, P; Stephens, TC1
Armand, JP; Faivre, S; Kayitalire, L; Le Chevalier, T; Lhommé, C; Lokiec, F; Monnerat, C; Novello, S; Pautier, P; Raymond, E; Ruffié, P; Taieb, J1
Joerger, M; Pestalozzi, BC; Walter, RB1
Fuxius, S; Mansouri, K; Mross, K; Unger, C1
Arcusa, A; Balil, A; Batiste-Alentorn, E; Carrasco, EM; Cirera, L; Font, A; Nogué, M; Perez-Gracia, JL; Tusquets, I1
Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D1
Gutierrez, M; Lhomme, C; Pautier, P1
André, T; Culine, S; Epaud, C; Gligorov, J1
Bergman, AM; Peters, GJ; Pinedo, HM; Smid, K; Van Moorsel, CJ; Voorn, DA1
Eaton, S; Fusco, N; Mossbruger, K; Rodriguez, M; Rose, PG; Smrekar, M1
Brewer, CA; DiSaia, PJ; Evans, SS; Kidder, WA; Minor, DR; Nagourney, RA; Radecki, S; Sommers, BL1
Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T1
Cullinane, C; Moufarij, MA; Phillips, DR1
Amant, F; Berteloot, P; D'Agostino, G; Scambia, G; Vergote, I1
Bilgin, T; Ozalp, S; Ozerkan, K; Vardar, MA; Yalçin, OT; Zorlu, G1
Makhnova, EV1
Gershanovich, ML; Makhnova, EV1
Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N1
Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T1
Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC1
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D2
Bookman, M; Copeland, LJ; Trimble, E1
Mutch, DG1
Fowler, WC; Van Le, L1
Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K2
Breda, E; D'Agostino, G; Ferrandina, G; Gbaguidi, N; Lorusso, D; Ludovisi, M; Mancuso, S; Scambia, G; Testa, A1
Beauduin, M; Belpomme, D; Canon, JL; De Pauw, A; Gauthier, S; Janssens, J; Kayitalire, L; Krakowski, I; Moreau, V; Petit, T1
D'Agostino, G; Ferrandina, G; Fruscella, E; Gallo, D; Scambia, G1
Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV1
Kennedy, AW; Khuntia, D; Markman, M; Schwartz, BM1
Kaye, SB; McMahon, L; Paul, J; Reed, N; Vasey, PA1
Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J1
Aravantinos, G; Briassoulis, E; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, C; Moulopoulos, LA; Papadimitriou, CA1
Geisler, JP; Manahan, KJ; Schraith, DF; Sorosky, JI1
Pfisterer, J1
Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P1
Barlow, C; Fennell, D; Gallagher, C; Ismay, J; Nystrom, M; Oesterling, C1
Friedlander, M; Harnett, P; Martin, A; Phillips, KA; Quinn, M; Richardson, G; Rischin, D1
Bahador, A; Facio, G; Garcia, AA; Jeffers, S; Kim, DY; O'Meara, A; Roman, L1
Aghajanian, C; Anderson, S; Bloss, J; Chi, D; Dizon, D; Dupont, J; Leitao, M; O'Flaherty, C; Sabbatini, P; Spriggs, D; Venkatraman, E1
A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R1
Piura, B1
Al-Madhoun, AS; Eriksson, S; Loves, WJ; Padron, JM; Peters, GJ; Talianidis, I; van der Wilt, CL1
Piura, B; Rabinovich, A1
Burger, RA; Falkner, CA; Hunter, M; Monk, BJ; Tewari, D1
Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H1
Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH1
Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA1
Hansen, SW; Larsen, FO1
Baba, T; Fujii, S; Mandai, M1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P1
Herzog, TJ1
Driscoll, DL; Lele, S; Marchetti, D; Odunsi, K; Rodabaugh, K; Villella, J1
Bader, K; Brown, JV; Goldstein, BH; Graham, C; Markman, M; Mattison, JA; Micha, JP; Rettenmaier, MA1
Aieta, M; De Giorgi, U; Fochessati, F; Marangolo, M; Paoluzzi, L; Papiani, G; Rosti, G; Valduga, F1
Akimoto, T; Hasegawa, K; Kishimoto, Y; Morimoto, Y; Sawai, T1
Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J1
Beslija, S; Fitzthum, E; Hayden, A; Kose, MF; Krejcy, K; Melemed, A; Minarik, T; Saip, P; Sufliarsky, J; Tulunay, G1
Belau, A; Burges, A; du Bois, A; Elser, G; Jackisch, C; Lueck, HJ; Olbricht, S; Pfisterer, J; Richter, B; Schmalfeldt, B; Schroeder, W; Staehle, A; Wagner, U1
Ditto, A; Fontanelli, R; Grijuela, B; Hanozet, F; Kusamura, S; Raspagliesi, F; Scibilia, G; Scollo, P; Solima, E; Spatti, G; Vecchione, F; Zanaboni, F1
Blessing, JA; Darcy, KM; Garcia, AA; Husseinzadeh, N; Lenz, HJ; Mannel, RS; Miller, DS1
Herzog, TJ; Lewin, SN; Liapis, H; Mutch, DG; Whitcomb, BP1
Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Kangasniemi, L; Raki, M; Ranki, T; Ristimaki, A; Sarkioja, M1
Arora, R; Awasthy, BS; Fuloria, J; Ganesh, N; Gupta, SK; John, S; Naik, R; Selvamani, B1
Adamo, V; Breda, E; D'Agostino, G; Ferrandina, G; Lorusso, D; Ludovisi, M; Paris, I; Pezzella, G; Pisconti, S; Scambia, G; Testa, A; Zanghi, M1
Ozols, RF4
Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S1
Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG1
Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH1
Ahmad, T; Gibbens, I; Gore, M; Habeshaw, T; Hubner, R; Kaye, S; Keyzor, C; Rothermundt, C1
Brown, S; Chen, EX; Chin, SF; Duran, I; Nottage, M; Oza, AM; Pond, GR; Siu, LL; Sturgeon, J1
Comijn, EC; Lakerveld, B; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Van der Vijgh, WJ; Van Moorsel, CJ; Voorn, D; Weaver, D; Willey, JC1
Poveda, A1
Lehoczky, O1
Markman, M2
Alvero, AB; Brown, D; Chen, W; Garg, M; Kelly, G; Mor, G; O'Malley, D; Rutherford, T1
Altevogt, P; Debatin, KM; Edler, L; Gutwein, P; Herr, I; Marmé, A; Mattern, J; Rittgen, W; Wenger, T; Zhang, C1
Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA1
Angleitner-Boubenizek, L; Deibl, M; Marth, C; Petru, E; Reinthaller, A; Stempfl, A; Volgger, B; Zeimet, AG1
Aghajanian, C; Chi, DS; Correa, DD; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Thaler, H; Venkatraman, E; Wilton, A1
Kose, MF; Meydanli, MM; Tulunay, G1
Atkinson, N; Bodurka, DC; Branham, D; Gershenson, DM; Jenkins, AD; Sun, CC; Verschraegen, C; Wolf, JK1
Alexandre, J; Chapron, C; Chopin, N; Goldwasser, F; Moachon, L1
Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L1
Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W1
Cheong, KA; Chrystal, K; Galani, E; Gallagher, C; Harper, PG; Lofts, F; Marx, GM; Steer, CB; Strickland, AH; Thomas, H; Yip, D1
Blessing, JA; Brewer, CA; Hanjani, P; Morgan, M; Nagourney, RA1
Odicino, F; Pasinetti, B; Pecorelli, S; Tisi, G1
Ledermann, JA; Pfisterer, J1
Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A1
Buesa, JM; Esteban, E; Gión, MO; Losa, R; Sierra, MI1
Neale, G; Qureshi, F1
Gibb, RK; Hagemann, A; Mutch, DG; Norris, L; Powell, MA; Rader, JS; Viviano, D; Wright, JD1
Boaz, M; Brenner, J; Golan, A; Grisaru, D; Hayat, H; Inbar, M; Levy, T; Menczer, J; Ron, I; Safra, T1
Case, AS; Estes, JM; Partridge, EE; Rocconi, RP; Straughn, JM1
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM1
Di Stefano, A; Fanfani, F; Lorusso, D; Scambia, G1
Arcuri, C; Galligioni, E; Griso, C; Sorio, R1
Götz, C; Harlozinska, A; Kartarius, S; Montenarh, M; Touma, R1
Fan, W; Kraft, AS; Sui, M; Xiong, X1
Akel, A; Bachmann, C; Dreischer, P; Eisele, K; Gulbins, E; Huober, J; Kempe, DS; Klarl, BA; Lang, F; Lang, PA; Niemoeller, OM; Sobiesiak, M; Wieder, T1
Bentley, J; du Bois, A; Eisenhauer, E; Emerich, J; Hirte, H; Jackisch, C; Kimmig, R; Kuhn, W; Lacave, AJ; Le, T; Lück, HJ; Olbricht, S; Pfisterer, J; Plante, M; Rochon, J; Stähle, A; Stuart, G; Vergote, I; Wagner, U; Zimmermann, AH1
Lehoczky, O; Pulay, T1
Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Koutsoukou, V; Papadimitriou, CA1
Ilanchadran, A; Tan, TY; Tay, SK1
DeVita, VT1
Meerum Terwogt, JM; Rodenhuis, S; Schellens, JH; van Boven, HH; van den Heuvel, MM; Veltkamp, SA1
Brames, MJ; Einhorn, LH; Juliar, B; Williams, SD1
Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E1
Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA1
Corrado, G; Ferrandina, G; Legge, F; Mey, V; Nannizzi, S; Petrillo, M; Ricciardi, S; Scambia, G1
Komiyama, S; Kurahashi, T; Kuwabara, Y; Mikami, M; Murakami, I; Nakamura, M; Tanaka, K1
Gordon, AN; Goss, T; Marciniack, M; McMeekin, SD; Mutch, DG; Naumann, RW; Orlando, M; Scribner, DR; Secord, AA; Teneriello, MG; Wang, Y1
Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA1
Aravantinos, G; Economopoulos, T; Gaglia, A; Gouveris, P; Koumarianou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N1
Kad, R; Kalra, N; Osama, S1
Bützow, R; Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Raki, M; Särkioja, M1
Huang, HF; Lang, JH; Pan, LY; Peng, P; Shen, K; Wu, M; Yang, JX1
Germano, D; Manzione, L; Rosati, G1
Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K1
Breda, E; Del Medico, P; Ferrandina, G; Katsaros, D; Lorusso, D; Ludovisi, M; Pignata, S; Priolo, D; Savarese, A; Scaltriti, L; Scambia, G1
Carone, V; Corrado, G; Ferrandina, G; Ludovisi, M; Petrillo, M; Scambia, G1
Behne, MJ; Brüllke, N; Hauswirth, U; Menz, A; Moll, I; Müllerleile, U1
Choi, SH; Han, SS; Kang, SB; Kim, JW; Lee, HP; Lee, YK; Park, NH; Song, YS1
Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E1
Eriksson, S; Peters, GJ; Ruiz van Haperen, VW; Stegmann, AP; Veerman, G1
Boven, E; Braakhuis, BJ; Peters, GJ; Ruiz van Haperen, VW; Veerman, G1
Bergman, AM; Braakhuis, BJ; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Veerman, G1
Neijt, JP1
Bergman, AM; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Veerman, G1
Eisenhauer, EA; Hansen, HH; Hansen, M; Neijt, JP; Piccart, MJ; Sessa, C; Thigpen, JT1
Hansen, M; Hansen, OP; Lund, B; Neijt, JP; Theilade, K2
Boven, E; Noordhuis, P; Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB1
Boven, E; Eriksson, S; Hermsen, M; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Stegmann, AP; Veerman, G; Vermorken, JB1
Boven, E; Erkelens, CA; Hatty, SA; Pinedo, HM; Schipper, H1
Fields, AL; Goldberg, GL; Runowicz, CD1
Peters, G; Pinedo, HM; van Haperen, VW; Veerman, G; Vermorken, JB1
Bokemeyer, C; Daikeler, T; Kanz, L; Maas, K1
Lund, B; Neijt, JP1
Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V1
Eisenhauer, EA; Vermorken, JB1
Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T1
Von Hoff, DD1
Kaufmann, M; von Minckwitz, G1
Pedersen, AG1
Bell, DR; Levi, JA; Millward, MJ; Pavlakis, N1
Awada, A; Klastersky, J1
Cartee, L; Kucera, GL1
Bergman, AM; Kroep, JR; Peters, GJ; Pinedo, HM; van Moorsel, CJ; Veerman, G; Vermorken, JB; Voorn, DA1
Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Veerman, G1
Brandner, G; Hess, RD; Merlin, T1
Augustine, K; Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vasuratna, A; Verschraegen, CF1
Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Smitskamp-Wilms, E; Veerman, G1
Bell, D; Bugat, R; Campbell, L; Friedlander, M; Harnett, P; Kayitalire, L; Millward, MJ; Moreno, JA; Ripoche, V; Varette, C1
Guechev, A; Loves, WJ; Peters, GJ; Pinedo, HM; Postmus, PE; Smid, K; van Moorsel, CJ; Veerman, G; Vermorken, JB1
Cartee, L; Kucera, GL; Nixon, JB1
Einhorn, LH; Stender, MJ; Williams, SD1
Brady, MF; McGuire, WP; Ozols, RF1
Hansen, SW; Sessa, C; Tuxen, MK1
Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Vermorken, JB1
Bauknecht, T; Neijt, JP; Visseren-Grul, CM; von Minckwitz, G1
Piver, MS; Silver, DF1
Cianci, C; Conte, PF; Gadducci, A1
Catik, A; Kroep, JR; Peters, GJ; Pinedo, HM; van Groeningen, CJ; van Moorsel, CJ; Vermorken, JB1
Bergman, AM; Kroep, JR; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; van Moorsel, CJ; Veerman, G; Voorn, DA1
Goldwasser, F; Gross, M; Hiesse, C; Kriaa, F1
Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A1
Bergman, AM; Giaccone, G; Mauritz, R; Noordhuis, P; Peters, GJ; Pinedo, HM; van Moorsel, CJ1
Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G1
Lambrou, N; Trimble, EL1
Abu-Rustum, N; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Hoskins, WJ; Husain, A; Poynor, EA; Prasad, M1
Cree, IA; Hindley, A; Kurbacher, CM; Lamont, A; Neale, MH1
D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G1
Banzato, F; Cappella, P; D'Incalci, M; Faretta, M; Lupi, M; Montalenti, F; Tomasoni, D; Ubezio, P; Viale, F1
Hansen, SW2
Mandachain, M; Orlando, M1
Chalas, E; Hindenburg, A; Jeyakumar, A1
Blohmer, JU; du Bois, A; Kimmig, R; Lück, HJ; Moebus, V; Pfisterer, J; Quaas, J; Schroeder, W1
Twelves, C1
Ahern, J; Carmichael, J; Dombernowsky, P; Hansen, H; Hansen, M; Harper, PG; Highley, MS; Hirsch, F; Lund, B; Parnis, FX; Underhill, CR; Williams, C1
De Vincenzo, R; Distefano, M; Ferlini, C; Gaggini, C; Mancuso, S; Scambia, G1
du Bois, A1
Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT1
D'Agostino, G; Farnetano, MG; Ferrandina, G; Garganese, G; Lorusso, D; Mancuso, S; Salerno, MG; Scambia, G1
Catalano, P; Einhorn, LH; Hinton, S; Kuzel, T; Loehrer, PJ; Vaughn, D; Wilding, G1
Fujiwaki, R; Hata, K; Iwanari, O; Katabuchi, H; Miyazaki, K; Moriyama, M; Nakayama, K; Okamura, H; Sakai, E1
Hensley, ML1
Ban, J; Weber, G1
Bhalla, K; Bullock, G; Holladay, C; Ibrado, AM; Jasiok, M; Lutzky, J; Singh, S1
Noordhuis, P; Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB1

Reviews

55 review(s) available for deoxycytidine and Ovarian Neoplasms

ArticleYear
Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Gynecologic oncology, 2019, Volume: 155, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic

2019
Precision medicine for ovarian clear cell carcinoma based on gene alterations.
    International journal of clinical oncology, 2020, Volume: 25, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Dosage; Glutathione; Humans; Molecular Targeted Therapy; Mutation; Ovarian Neoplasms; Precision Medicine; Transcription Factors

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
    Medical oncology (Northwood, London, England), 2020, Jun-11, Volume: 37, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome

2020
Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:6

    Topics: Adult; Cardiomyopathy, Dilated; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Stroke Volume; Ventricular Function, Left

2021
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    The Cochrane database of systematic reviews, 2018, 10-16, Volume: 10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic

2018
Slow progression of calcified cerebellar metastasis from ovarian cancer: a case report and review of the literature.
    Neurologia medico-chirurgica, 2013, Volume: 53, Issue:10

    Topics: Adenocarcinoma, Mucinous; Adult; Antimetabolites, Antineoplastic; Calcinosis; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Disease Progression; Encephalocele; Female; Gemcitabine; Humans; Hydrocephalus; Hysterectomy; Magnetic Resonance Imaging; Ovarian Neoplasms; Ovariectomy; Tomography, X-Ray Computed

2013
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2015, Volume: 19, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom

2015
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids

2015
[LEIOMYOSARCOMA ARISING FROM OVARIAN VEIN WITH RIGHT HYDRONEPHROSIS: A CASE REPORT].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2015, Volume: 106, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hydronephrosis; Leiomyosarcoma; Ovarian Neoplasms; Taxoids; Tomography, X-Ray Computed; Vena Cava, Inferior

2015
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
    Gynecologic oncology, 2016, Volume: 140, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult

2016
Overcoming platinum resistance in ovarian carcinoma.
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms

2010
Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
    The oncologist, 2010, Volume: 15, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols

2010
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    The Cochrane database of systematic reviews, 2011, Oct-05, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic

2011
First-line chemotherapy in epithelial ovarian cancer.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1

    Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A

2012
A rational approach to the management of recurrent or persistent ovarian carcinoma.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic

2012
Gemcitabine-associated hemolytic-uremic syndrome.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:4

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Ovarian Neoplasms; Ribonucleotide Reductases

2002
[Gemicitabine in the treatment of epithelial ovarian cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

2002
Gemcitabine combination chemotherapy of ovarian cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:2 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy

2003
Gemcitabine as a single-agent treatment for ovarian cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:2 Pt 2

    Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms

2003
Gemcitabine: current role and future options in the treatment of ovarian cancer.
    Critical reviews in oncology/hematology, 2003, Volume: 48, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome

2003
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
    Gynecologic oncology, 2004, Volume: 94, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Epithelial Cells; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms

2004
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Peritoneal Neoplasms; Vascular Endothelial Growth Factor A

2004
Recurrent ovarian cancer: how important is it to treat to disease progression?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan

2004
Gemcitabine and carboplatin in second-line ovarian cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate

2005
Gemcitabine in patients with ovarian cancer.
    Cancer treatment reviews, 2005, Volume: 31 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Remission Induction

2005
[Review of effectiveness of chemotherapy with gemcitabine in ovarian cancer].
    Orvosi hetilap, 2005, Nov-13, Volume: 146, Issue:46

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome

2005
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Survival

2006
Role of gemcitabine in cancer therapy.
    Future oncology (London, England), 2005, Volume: 1, Issue:1

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms

2005
Optimizing gemcitabine regimens in ovarian cancer.
    Seminars in oncology, 2006, Volume: 33, Issue:2 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic

2006
Management of platinum-sensitive recurrent ovarian cancer.
    Seminars in oncology, 2006, Volume: 33, Issue:2 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel

2006
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
    Seminars in oncology, 2006, Volume: 33, Issue:2 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic

2006
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:8

    Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan

2006
Role of gemcitabine in ovarian cancer treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Survival Analysis; Treatment Outcome

2006
New cytostatic drugs in ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic

1993
Promising new therapies in the treatment of advanced ovarian cancer.
    Cancer, 1995, Nov-15, Volume: 76, Issue:10 Suppl

    Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan

1995
Gemcitabine in cisplatin-resistant ovarian cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:5 Suppl 10

    Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms

1996
New drugs in gynecologic oncology.
    Current opinion in oncology, 1996, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Platinum Compounds; Uterine Cervical Neoplasms

1996
Gemcitabine in ovarian cancer: an overview of safety and efficacy.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33 Suppl 1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms

1997
Future directions in the chemotherapy of ovarian cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine

1997
[Gemcitabine: a new chemotherapy agent for solid cancers].
    Revue medicale de Bruxelles, 1997, Volume: 18, Issue:5

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents

1997
Gemcitabine in the treatment of ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

1999
Up date in the management of advanced ovarian carcinoma.
    Critical reviews in oncology/hematology, 1999, Volume: 32, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan

1999
The role of gemcitabine in the treatment of ovarian cancer.
    Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis

2000
Dose-intensive approaches to ovarian cancer.
    Current oncology reports, 1999, Volume: 1, Issue:1

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis; Survival Analysis; Topotecan

1999
The current role of gemcitabine in ovarian cancer.
    Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms

2001
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2001, Volume: 11 Suppl 1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan

2001
Gemcitabine in ovarian cancer.
    Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms

2001
Vision of the future: capecitabine.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Ovarian Neoplasms; Pancreatic Neoplasms

2001
Treatment of advanced ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37 Suppl 9

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan

2001
Second-line treatment of ovarian cancer with single-agent gemcitabine.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms

2002
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2002
Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel

2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan

2002
Epithelial ovarian cancer.
    Current treatment options in oncology, 2002, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine

2002

Trials

147 trial(s) available for deoxycytidine and Ovarian Neoplasms

ArticleYear
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
    Nature communications, 2021, 09-22, Volume: 12, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Deoxycytidine; DNA Replication; Female; Gemcitabine; Humans; Isoxazoles; Mutation; Oncogenes; Ovarian Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Recombinational DNA Repair; Retinoblastoma Binding Proteins

2021
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
    Anti-cancer drugs, 2023, 08-01, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms

2023
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan

2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecologic oncology, 2020, Volume: 156, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Progression-Free Survival; Pyridines; Young Adult

2020
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome

2020
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Journal of ovarian research, 2020, Feb-07, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.
    Journal of gynecologic oncology, 2021, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Platinum

2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet (London, England), 2021, 01-23, Volume: 397, Issue:10271

    Topics: Antimetabolites, Antineoplastic; Canada; Deoxycytidine; Double-Blind Method; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles; Pyrimidinones; Survival; United States

2021
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PloS one, 2021, Volume: 16, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CA-125 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Progression-Free Survival; Survival Rate; Treatment Outcome

2021
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecologic oncology, 2021, Volume: 162, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasm Staging; Ovarian Neoplasms

2021
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting

2017
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
    Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols

2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome

2017
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecologic oncology, 2018, Volume: 148, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome

2018
Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
    Minerva ginecologica, 2019, Volume: 71, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Topotecan

2019
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult

2013
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
    Gynecologic oncology, 2013, Volume: 130, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Thrombocytopenia

2013
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate

2013
Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:6

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cystadenocarcinoma, Serous; Deoxycytidine; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Prognosis; Quality of Life; Survival Rate

2013
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
    Journal of experimental & clinical cancer research : CR, 2013, Aug-08, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Salvage Therapy

2013
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
    Gynecologic oncology, 2014, Volume: 133, Issue:1

    Topics: Adult; Advisory Committees; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiology; Tomography, X-Ray Computed

2014
A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
    Gynecologic oncology, 2014, Volume: 134, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms

2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult

2014
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
    Gynecologic oncology, 2015, Volume: 136, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Republic of Korea; Vinblastine; Vinorelbine

2015
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hydroxamic Acids; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Vorinostat

2015
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecologic oncology, 2015, Volume: 139, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Rate

2015
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
    Oncotarget, 2015, Oct-13, Volume: 6, Issue:31

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer Vaccines; Cells, Cultured; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Interferon alpha-2; Interferon-alpha; Lymphocytes, Tumor-Infiltrating; Middle Aged; Netherlands; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Recombinant Proteins; T-Lymphocytes; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53

2015
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
    British journal of cancer, 2015, Dec-01, Volume: 113, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Endometrial Neoplasms; Female; Furans; Gemcitabine; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Ontario; Ovarian Neoplasms; Response Evaluation Criteria in Solid Tumors; Treatment Outcome

2015
Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer.
    Anticancer research, 2016, Volume: 36, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retroperitoneal Space; Taxoids

2016
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
    British journal of clinical pharmacology, 2016, Volume: 82, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Analysis

2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan

2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan

2016
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
    Gynecologic oncology, 2008, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan

2008
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-01, Volume: 26, Issue:19

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome

2008
Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.
    International journal of clinical oncology, 2008, Volume: 13, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy

2008
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dietary Supplements; Drug Administration Schedule; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Maximum Tolerated Dose; Neoplasms; Neutropenia; Ovarian Neoplasms; Pemetrexed; Treatment Outcome; Vitamin B Complex

2008
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial.
    American journal of clinical oncology, 2008, Volume: 31, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Ribonucleotide Reductases; Survival Rate

2008
Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pemetrexed; Platinum Compounds; Salvage Therapy; Survival Analysis; Treatment Outcome

2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
    British journal of cancer, 2009, Feb-24, Volume: 100, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Taxoids

2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan

2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Survival Analysis

2009
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
    Thrombosis research, 2009, Volume: 124, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism

2009
A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer.
    Anticancer research, 2009, Volume: 29, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Taxoids

2009
A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism.
    Chemotherapy, 2009, Volume: 55, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Taxoids

2009
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
    Gynecologic oncology, 2009, Volume: 115, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life; Topotecan; Treatment Outcome

2009
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
    Gynecologic oncology, 2009, Volume: 115, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms

2009
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-01, Volume: 28, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Fallopian Tube Neoplasms; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger

2010
Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Recurrence; Survival Analysis; Vinblastine; Vinorelbine

2009
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult

2009
[Final results of cooperative studies of dicarbamine used as a hemoprotector in combination chemotherapy for cancer].
    Voprosy onkologii, 2009, Volume: 55, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caproates; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hematinics; Humans; Imidazoles; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome

2009
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Prospective Studies; Treatment Outcome; Vinblastine; Vinorelbine

2011
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2010
Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Gynecologic oncology, 2010, Volume: 118, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Survival Rate

2010
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Gynecologic oncology, 2010, Volume: 119, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate

2010
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Italy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome

2010
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Time Factors; Treatment Outcome

2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-20, Volume: 28, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Young Adult

2010
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2010
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate; Treatment Outcome

2010
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.
    European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:4

    Topics: Adult; Deoxycytidine; Deoxyribonucleosides; Female; Humans; Lymphoma; Male; Metabolic Networks and Pathways; Ovarian Neoplasms; Positron-Emission Tomography; Radiometry; Young Adult

2011
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
    Zhonghua fu chan ke za zhi, 2010, Volume: 45, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome

2010
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tissue Distribution; Treatment Outcome

2011
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult

2011
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome

2011
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
    Gynecologic oncology, 2012, Volume: 124, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate

2012
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2012, Volume: 124, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult

2012
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
    Cancer investigation, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids

2012
Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Compliance; Pilot Projects; Prospective Studies; Ultrasonography, Interventional

2012
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers.
    American journal of clinical oncology, 2014, Volume: 37, Issue:4

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms

2014
Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Recurrence; Treatment Outcome

2013
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin I; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Thrombocytopenia

2013
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome

2002
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome

2002
Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms

2002
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Probability; Survival Analysis; Topotecan; Treatment Failure; Treatment Outcome

2002
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
    Gynecologic oncology, 2003, Volume: 88, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms

2003
Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.
    Gynecologic oncology, 2003, Volume: 88, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Receptor, ErbB-2

2003
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
    Gynecologic oncology, 2003, Volume: 88, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy

2003
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
    Gynecologic oncology, 2003, Volume: 89, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids

2003
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
    American journal of obstetrics and gynecology, 2003, Volume: 188, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington

2003
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
    Gynecologic oncology, 2003, Volume: 90, Issue:2 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan

2003
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel

2003
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
    British journal of cancer, 2003, Oct-06, Volume: 89, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Treatment Outcome

2003
Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.
    Gynecologic oncology, 2003, Volume: 91, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Survival Rate

2003
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
    Gynecologic oncology, 2003, Volume: 91, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan

2003
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
    British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life

2003
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2004
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies

2004
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
    Onkologie, 2004, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure

2004
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
    British journal of cancer, 2004, Apr-05, Volume: 90, Issue:7

    Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Transplantation, Autologous

2004
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
    Gynecologic oncology, 2004, Volume: 93, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms

2004
Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
    Gynecologic oncology, 2004, Volume: 93, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel

2004
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting

2004
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
    British journal of cancer, 2004, Aug-16, Volume: 91, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2004
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Gynecologic oncology, 2004, Volume: 94, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy

2004
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Gynecologic oncology, 2004, Volume: 94, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects

2004
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
    Gynecologic oncology, 2005, Volume: 96, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel

2005
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
    American journal of clinical oncology, 2004, Volume: 27, Issue:5

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Male; Mediastinal Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Analysis; Testicular Neoplasms

2004
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
    Gynecologic oncology, 2005, Volume: 96, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms

2005
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
    Gynecologic oncology, 2005, Volume: 96, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel

2005
Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
    Oncology, 2004, Volume: 67, Issue:5-6

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome

2004
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2005, Volume: 96, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Screening Assays, Antitumor; Female; Fluorouracil; Gene Expression; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Thymidine Phosphorylase; Thymidylate Synthase

2005
A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
    Gynecologic oncology, 2005, Volume: 98, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel

2005
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
    Gynecologic oncology, 2005, Volume: 98, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Survival Rate

2005
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2006, Volume: 100, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan

2006
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
    Gynecologic oncology, 2006, Volume: 101, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel

2006
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.
    British journal of cancer, 2006, Jan-16, Volume: 94, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome

2006
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
    Anti-cancer drugs, 2006, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms

2006
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
    British journal of cancer, 2006, Jan-16, Volume: 94, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome

2006
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
    Gynecologic oncology, 2006, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life

2006
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
    Gynecologic oncology, 2006, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cognition; Cognition Disorders; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Longitudinal Studies; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life

2006
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
    Gynecologic oncology, 2006, Volume: 102, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids

2006
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
    British journal of cancer, 2006, May-22, Volume: 94, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate

2006
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
    Gynecologic oncology, 2006, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Rate

2006
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
    Gynecologic oncology, 2006, Volume: 103, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms

2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
    Gynecologic oncology, 2006, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2006
Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Treatment Outcome

2006
Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2006, Volume: 18, Issue:1-3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Calcium; Carboplatin; Cell Size; Ceramides; Deoxycytidine; Endometrial Neoplasms; Erythrocytes; Female; Gemcitabine; Hematocrit; Humans; Mice; Mice, Inbred C57BL; Osmotic Pressure; Ovarian Neoplasms; Paclitaxel; Phosphatidylserines; Protein Binding; Sphingomyelin Phosphodiesterase; Time Factors

2006
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-10, Volume: 24, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome

2006
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
    Gynecologic oncology, 2007, Volume: 104, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2007
First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study.
    BJOG : an international journal of obstetrics and gynaecology, 2006, Volume: 113, Issue:12

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome

2006
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Indiana; Kaplan-Meier Estimate; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Time Factors; Treatment Failure; Treatment Outcome

2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
    Investigational new drugs, 2007, Volume: 25, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance

2007
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Treatment Outcome

2007
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols

2008
Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2007, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds

2007
Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Salvage Therapy

2007
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Treatment Outcome

2008
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Gynecologic oncology, 2008, Volume: 109, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Survival Analysis

2008
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
    Journal of the National Cancer Institute, 1994, Oct-19, Volume: 86, Issue:20

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Survival Analysis; Treatment Outcome

1994
Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
    Anti-cancer drugs, 1995, Volume: 6 Suppl 6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Time Factors

1995
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
    Gynecologic oncology, 1996, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome

1996
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms

1996
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
    Seminars in oncology, 1997, Volume: 24, Issue:2 Suppl 7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases

1997
Mechanisms of synergism between gemcitabine and cisplatin.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; RNA, Neoplasm; Tumor Cells, Cultured

1998
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fever; Gemcitabine; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Quality of Life; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome

1998
Phase II trial of gemcitabine in refractory germ cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Germinoma; Humans; Male; Middle Aged; Ovarian Neoplasms; Testicular Neoplasms

1999
Phase II study of gemcitabine in ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:7

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life

1999
Gemcitabine-cisplatin: a schedule finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Leukopenia; Linear Models; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia

1999
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome

2000
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2000, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia

2000
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
    Oncology, 2001, Volume: 60, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome

2001
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer.
    Anti-cancer drugs, 2001, Volume: 12, Issue:8

    Topics: Adult; Aged; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome

2001
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.
    Oncology, 2002, Volume: 62, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukocytes; Liposomes; Middle Aged; Ovarian Neoplasms; Treatment Outcome

2002
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Germinoma; Humans; Infusions, Intravenous; Male; Ovarian Neoplasms; Paclitaxel; Seminoma; Testicular Neoplasms; Treatment Outcome; United States

2002

Other Studies

232 other study(ies) available for deoxycytidine and Ovarian Neoplasms

ArticleYear
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Nivolumab; Ovarian Neoplasms; Polyethylene Glycols

2022
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
    International journal of clinical oncology, 2022, Volume: 27, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Ovarian Neoplasms; Platinum

2022
MiR-624-5p enhances NLRP3 augmented gemcitabine resistance via EMT/IL-1β/Wnt/β-catenin signaling pathway in ovarian cancer.
    Journal of reproductive immunology, 2022, Volume: 150

    Topics: beta Catenin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; NLR Family, Pyrin Domain-Containing 3 Protein; Ovarian Neoplasms; Wnt Signaling Pathway

2022
Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery.
    Drug delivery, 2022, Volume: 29, Issue:1

    Topics: Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms

2022
Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells.
    Journal of microencapsulation, 2022, Volume: 39, Issue:5

    Topics: Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Liposomes; Nanoparticles; Ovarian Neoplasms; Oxaliplatin

2022
Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
    Cancer medicine, 2023, Volume: 12, Issue:8

    Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome

2023
Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
    Drug design, development and therapy, 2019, Volume: 13

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; China; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Ovarian Neoplasms; Particle Size; Rats

2019
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecologic oncology, 2019, Volume: 155, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Knockout Techniques; HCT116 Cells; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Middle Aged; Nuclear Proteins; Ovarian Neoplasms; Random Allocation; Transcription Factors; Xenograft Model Antitumor Assays

2019
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Gynecologic oncology, 2019, Volume: 155, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines

2019
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate

2020
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B

2020
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies

2021
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan

2020
Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine.
    The journal of obstetrics and gynaecology research, 2021, Volume: 47, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies

2021
A source of hope for platinum-resistant ovarian cancer?
    Lancet (London, England), 2021, 01-23, Volume: 397, Issue:10271

    Topics: Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Pyrazoles; Pyrimidinones

2021
Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics.
    International journal of nanomedicine, 2021, Volume: 16

    Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Endocytosis; Female; Folic Acid; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Particle Size; Rats, Sprague-Dawley; Tissue Distribution; Ultrasonics

2021
WEE1 inhibition after platinum resistance.
    Nature reviews. Clinical oncology, 2021, Volume: 18, Issue:4

    Topics: Cell Cycle Proteins; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones

2021
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
    Cancer medicine, 2021, Volume: 10, Issue:6

    Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms

2021
[Clinical Application of Gemcitabine plus Cisplatin plus Bevacizumab Combination Chemotherapy for Ovarian Clear Cell Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms

2021
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
    International journal of molecular sciences, 2021, Apr-29, Volume: 22, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Hydrazones; In Vitro Techniques; Mathematical Concepts; Models, Biological; Ovarian Neoplasms; Piperazines; TNF-Related Apoptosis-Inducing Ligand

2021
Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.
    Japanese journal of clinical oncology, 2017, Jun-01, Volume: 47, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Demography; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Prognosis

2017
    Bulletin du cancer, 2017, Volume: 104 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan

2017
Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.
    International journal of nanomedicine, 2017, Volume: 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metal Nanoparticles; Ovarian Neoplasms; Resveratrol; Silver; Stilbenes

2017
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin

2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids

2018
Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
    European journal of gynaecological oncology, 2017, Volume: 38, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies

2017
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
    European journal of gynaecological oncology, 2017, Volume: 38, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan

2017
GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    International journal of cancer, 2018, 12-15, Volume: 143, Issue:12

    Topics: Alkaline Phosphatase; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Female; GATA3 Transcription Factor; Gemcitabine; Histone Demethylases; Humans; Neoplastic Stem Cells; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Spheroids, Cellular

2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
    Cancer discovery, 2018, Volume: 8, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles

2018
Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Artemisinins; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Heme Oxygenase-1; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Reactive Oxygen Species; Signal Transduction; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2019
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
    Scientific reports, 2018, 11-06, Volume: 8, Issue:1

    Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genome, Human; Humans; Machine Learning; Neoplasms; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Support Vector Machine; Transcriptome

2018
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
    The AAPS journal, 2019, 01-31, Volume: 21, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Data Interpretation, Statistical; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Mice; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2019
Expression profile and prognostic value of SFN in human ovarian cancer.
    Bioscience reports, 2019, 05-31, Volume: 39, Issue:5

    Topics: 14-3-3 Proteins; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exoribonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Messenger

2019
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 09-01, Volume: 25, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate

2019
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
    Scientific reports, 2019, 05-21, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms

2019
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
    Acta pharmaceutica (Zagreb, Croatia), 2019, Mar-01, Volume: 69, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult

2019
Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-20, Volume: 31, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Female; Gastric Fistula; Gemcitabine; Humans; Intestinal Fistula; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms

2013
Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.
    British journal of cancer, 2013, Apr-16, Volume: 108, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; CD24 Antigen; Cell Growth Processes; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Macrophages; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2013
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Cancer research, 2013, Jun-15, Volume: 73, Issue:12

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan

2013
BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
    The international journal of biochemistry & cell biology, 2013, Volume: 45, Issue:7

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; NF-kappa B; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; rho GTP-Binding Proteins; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2013
Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin

2013
18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients.
    Clinical nuclear medicine, 2013, Volume: 38, Issue:7

    Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Positron-Emission Tomography; Recurrence; Tomography, X-Ray Computed

2013
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
    International journal of cancer, 2013, Nov-15, Volume: 133, Issue:10

    Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays

2013
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate

2013
NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
    The Lancet. Oncology, 2013, Volume: 14, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome

2013
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
    International journal of pharmaceutics, 2013, Sep-15, Volume: 454, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cathepsin B; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Stability; Drug Synergism; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Male; Molecular Weight; Ovarian Neoplasms; Paclitaxel; Polymerization; Polymethacrylic Acids; Solubility; Technology, Pharmaceutical

2013
Gemcitabine therapy-associated cutaneous vasculitis with a polyarteritis nodosa-like pattern.
    International journal of dermatology, 2013, Volume: 52, Issue:8

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Polyarteritis Nodosa; Vasculitis, Leukocytoclastic, Cutaneous

2013
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
    International journal of clinical oncology, 2014, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms

2014
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Gene Amplification; Histones; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Micronuclei, Chromosome-Defective; Myeloid Cell Leukemia Sequence 1 Protein; N-Myc Proto-Oncogene Protein; Nuclear Proteins; Oncogene Proteins; Ovarian Neoplasms; Peptide Initiation Factors; Real-Time Polymerase Chain Reaction; RNA-Binding Proteins

2013
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Anti-cancer drugs, 2014, Volume: 25, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies

2014
Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: A case report.
    Asia-Pacific journal of clinical oncology, 2016, Volume: 12, Issue:1

    Topics: Abducens Nerve Diseases; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms

2016
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
    British journal of cancer, 2014, Jan-07, Volume: 110, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Ovarian Neoplasms; Reoviridae; T-Lymphocytes; Virus Replication

2014
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemorrhage; Hepatectomy; Humans; Liver Neoplasms; Ovarian Neoplasms; Sigmoid Neoplasms

2013
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bias; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Research Design; Treatment Failure; Triple Negative Breast Neoplasms

2014
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2013
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Journal of ovarian research, 2014, Apr-09, Volume: 7

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
Human ovarian cancer multicellular spheroids: a model for testing antiproliferation activity of Devil's club (Oplopanax horridus) and anticancer agents.
    Planta medica, 2014, Volume: 80, Issue:8-9

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Oplopanax; Ovarian Neoplasms; Paclitaxel; Plant Bark; Plant Extracts; Plants, Medicinal; Proteome; Spheroids, Cellular; Tumor Cells, Cultured

2014
Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Treatment Outcome

2014
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Aug-19, Volume: 111, Issue:33

    Topics: Acrylamides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2014
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    BMC cancer, 2014, Aug-07, Volume: 14

    Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea

2014
Anion exchange chromatography for the determination of 5-methyl-2'-deoxycytidine: application to cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
    Analytical and bioanalytical chemistry, 2015, Volume: 407, Issue:9

    Topics: Anion Exchange Resins; Antineoplastic Agents; Cell Line, Tumor; Chromatography, Ion Exchange; Cisplatin; Deoxycytidine; DNA Methylation; Female; Humans; Ovarian Neoplasms

2015
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:20

    Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed

2014
Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.
    Nanomedicine (London, England), 2014, Volume: 9, Issue:14

    Topics: Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanomedicine; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years

2014
Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
    Cancer letters, 2015, Apr-10, Volume: 359, Issue:2

    Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Nanocapsules; Ovarian Neoplasms

2015
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
    Indian journal of cancer, 2014, Volume: 51 Suppl 3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2014
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
    Indian journal of cancer, 2014, Volume: 51 Suppl 3

    Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2014
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
    Cell death & disease, 2015, Jun-18, Volume: 6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gemcitabine; Glutathione; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein Folding; Quinuclidines; Random Allocation; Taxoids; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
    Gynecologic oncology, 2015, Volume: 139, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult

2015
[A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Recurrence

2015
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan

2015
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
    Voprosy onkologii, 2015, Volume: 61, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines

2015
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore

2015
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
    Anti-cancer drugs, 2016, Volume: 27, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases

2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
    Gynecologic oncology, 2016, Volume: 140, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult

2016
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate

2016
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan

2016
Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.
    Chemotherapy, 2016, Volume: 61, Issue:5

    Topics: Administration, Oral; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Prednisone; Skin; Treatment Outcome

2016
Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells.
    Molecular pharmaceutics, 2016, 05-02, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Nanoparticles; Ovarian Neoplasms; Peptides; Peptides, Cyclic; Polymers; Reactive Oxygen Species

2016
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
    Oncotarget, 2016, Apr-19, Volume: 7, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV-Like Protein 1; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Protein Transport; Protein-Tyrosine Kinases; Retrospective Studies

2016
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
    Oncotarget, 2016, May-03, Volume: 7, Issue:18

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Proliferation; Deoxycytidine; Dioxoles; Doxorubicin; Female; Gemcitabine; Humans; Mice; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Polyethylene Glycols; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
    Journal of the Egyptian National Cancer Institute, 2016, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum

2016
Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
    Molecular pharmaceutics, 2016, 11-07, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Platinum; Polymers; Treatment Outcome

2016
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.
    The journal of obstetrics and gynaecology research, 2017, Volume: 43, Issue:2

    Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms

2017
Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
    Medicine, 2016, Volume: 95, Issue:51

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Young Adult

2016
The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
    Biochimica et biophysica acta. Molecular basis of disease, 2017, Volume: 1863, Issue:4

    Topics: Administration, Metronomic; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Ovarian Neoplasms; Telomere Homeostasis; Telomeric Repeat Binding Protein 2

2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Gynecologic oncology, 2017, Volume: 144, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies

2017
Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
    Molecular pharmaceutics, 2017, 05-01, Volume: 14, Issue:5

    Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polymers; Xenograft Model Antitumor Assays

2017
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Female; Fluorouracil; Humans; Ileal Neoplasms; Jejunal Neoplasms; Middle Aged; Ovarian Neoplasms; Ovariectomy; Oxaloacetates; Recurrence

2016
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:4

    Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Osteosarcoma; Ovarian Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays

2017
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult

2017
Gemcitabine pulmonary toxicity in ovarian cancer.
    The oncologist, 2008, Volume: 13, Issue:7

    Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Palliative Care; Pneumonia

2008
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
    Gynecologic oncology, 2008, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan

2008
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies

2008
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure

2009
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
    Gynecologic oncology, 2009, Volume: 113, Issue:2

    Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan

2009
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies

2009
Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.
    The Journal of reproductive medicine, 2009, Volume: 54, Issue:4

    Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Cholecystectomy; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fallopian Tubes; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Testosterone; Tomography, X-Ray Computed; Ultrasonography

2009
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Neoplasma, 2009, Volume: 56, Issue:4

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease Progression; Endometrial Neoplasms; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult

2009
Acute rhabdomyolysis as a complication of paclitaxel-gemcitabine chemotherapy for ovarian cancer.
    European journal of obstetrics, gynecology, and reproductive biology, 2009, Volume: 145, Issue:2

    Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Rhabdomyolysis

2009
[Phalanges necrosis--a rare manifestation of "hand-foot" syndrome induced by gemcitabine used in the second--line therapy for progressive ovarian cancer. A case report].
    Ginekologia polska, 2009, Volume: 80, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Finger Phalanges; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Necrosis; Ovarian Neoplasms; Syndrome

2009
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Remission Induction; Splenic Neoplasms; Thrombocytopenia

2010
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
    Anticancer research, 2009, Volume: 29, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Salvage Therapy

2009
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4

    Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Membrane Transport Proteins; Middle Aged; Nucleoside Transport Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins

2010
Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
    Prescrire international, 2009, Volume: 18, Issue:102

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Approval; Europe; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases

2009
ABC transporter gene expression in benign and malignant ovarian tissue.
    Gynecologic oncology, 2010, Volume: 117, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation

2010
Ovarian metastasis following gallbladder carcinoma: a case report.
    European journal of gynaecological oncology, 2010, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Incidental Findings; Lymph Node Excision; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Treatment Outcome

2010
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
    British journal of cancer, 2010, Aug-24, Volume: 103, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan

2010
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
    Toxicology in vitro : an international journal published in association with BIBRA, 2010, Volume: 24, Issue:8

    Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan

2010
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
    International journal of dermatology, 2010, Volume: 49, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neprilysin; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sister Mary Joseph's Nodule; Skin Neoplasms; Treatment Outcome; Umbilicus; Vimentin; WT1 Proteins

2010
Simultaneous breast and ovarian metastasis from gallbladder carcinoma.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2010, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Mastectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Salpingectomy

2010
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Congenital retroperitoneal vascular anomalies: impact on pelvic surgery.
    Archives of gynecology and obstetrics, 2011, Volume: 284, Issue:5

    Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Pelvis; Radiography; Treatment Outcome; Vascular Malformations; Vena Cava, Inferior

2011
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan

2010
Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2011, Volume: 51, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Intestinal Obstruction; Intestine, Small; Liver Neoplasms; Membrane Proteins; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Fibrosis; Treatment Outcome

2011
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult

2011
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome

2011
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan

2011
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
    Gynecologic oncology, 2011, Volume: 122, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Deoxycytidine; Doxorubicin; Enzyme Activation; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation

2011
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adenine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cytostatic Agents; Deoxycytidine; DNA Breaks, Double-Stranded; Doxorubicin; Drug Combinations; Drug Screening Assays, Antitumor; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Histones; HIV Reverse Transcriptase; Humans; Organophosphonates; Organophosphorus Compounds; Ovarian Neoplasms; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors

2012
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
    Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome

2011
[A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Humans; Neoplasm Staging; Ovarian Neoplasms; Oxaloacetates; Rectal Neoplasms; Tomography, X-Ray Computed

2011
Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer.
    Acta obstetricia et gynecologica Scandinavica, 2011, Volume: 90, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hand; Humans; Ischemia; Middle Aged; Ovarian Neoplasms

2011
Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management.
    Gynecologic oncology, 2012, Volume: 124, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Mitomycin; Ovarian Neoplasms; Palliative Care; Survival Rate; Treatment Outcome

2012
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids

2013
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
    Voprosy onkologii, 2011, Volume: 57, Issue:4

    Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms

2011
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
    Cancer letters, 2012, Jun-01, Volume: 319, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms

2012
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
    Anticancer research, 2012, Volume: 32, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan

2012
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:4

    Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Sulfonamides

2012
Noxa enhances the cytotoxic effect of gemcitabine in human ovarian cancer cells.
    Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Plasmids; Proto-Oncogene Proteins c-bcl-2; Transfection

2012
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate

2012
Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.
    International journal of clinical oncology, 2013, Volume: 18, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Camptothecin; Deoxycytidine; Female; Humans; Male; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Taxoids

2013
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
    International journal of oncology, 2012, Volume: 41, Issue:1

    Topics: Antimetabolites, Antineoplastic; Biosynthetic Pathways; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Glycosylation; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polysaccharides; Principal Component Analysis; Protein Processing, Post-Translational; Signal Transduction; Transcription, Genetic

2012
Malignant fibrous histiocytoma of the ovary: a case report.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids

2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
    The oncologist, 2012, Volume: 17, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Creatinine; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Quality of Life; Recurrence; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Taxoids; Thrombosis; Topotecan

2012
sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
    Apoptosis : an international journal on programmed cell death, 2012, Volume: 17, Issue:10

    Topics: Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2012
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
    BMC cancer, 2012, Aug-29, Volume: 12

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays

2012
Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Taxoids

2012
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
    BMC cancer, 2012, Sep-28, Volume: 12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histones; Homologous Recombination; Humans; Melphalan; Multiple Myeloma; Ovarian Neoplasms; Rad51 Recombinase; Signal Transduction

2012
[Chemotherapy for recurrent ovarian cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Topotecan

2012
[Treatment of recurrent ovarian cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan

2012
Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovarian cancer.
    Current drug delivery, 2013, Volume: 10, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cell Adhesion; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Drug Delivery Systems; Female; Fibrin; Gemcitabine; Humans; Nanocomposites; Ovarian Neoplasms; Pectins; Porosity; Tissue Scaffolds

2013
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2002
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine

2002
Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    International journal of oncology, 2003, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Deoxyribonucleotides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ovarian Neoplasms; Ribonucleotides; Tumor Cells, Cultured

2003
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids

2003
Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
    Molecular pharmacology, 2003, Volume: 63, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Adducts; DNA Damage; DNA Repair; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured

2003
Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients.
    European journal of gynaecological oncology, 2003, Volume: 24, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome

2003
[Combination chemotherapy with Hemzar (gemcitabine) and cisplatin for relapsing and cisplatin-resistant ovarian cancer].
    Voprosy onkologii, 2003, Volume: 49, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Recurrence; Treatment Outcome

2003
[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
    Voprosy onkologii, 2003, Volume: 49, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prodrugs; Treatment Outcome

2003
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
    Journal of neuro-oncology, 2003, Volume: 63, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases

2003
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
    The journal of obstetrics and gynaecology research, 2003, Volume: 29, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure

2003
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.
    Gynecologic oncology, 2003, Volume: 91, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiodermatitis

2003
Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer.
    Gynecologic oncology, 2004, Volume: 92, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Enterocolitis, Necrotizing; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Vasculitis

2004
Recurrent ovarian cancer.
    Onkologie, 2004, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure

2004
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
    Gynecologic oncology, 2004, Volume: 93, Issue:1

    Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan

2004
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
    Gynecologic oncology, 2004, Volume: 93, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan

2004
Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma.
    Archives of gynecology and obstetrics, 2005, Volume: 271, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome

2005
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Biochemical pharmacology, 2004, Aug-15, Volume: 68, Issue:4

    Topics: Alternative Splicing; Amino Acid Sequence; Animals; Antimetabolites, Antineoplastic; Base Sequence; Cell Line; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Molecular Sequence Data; Ovarian Neoplasms; Rats; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured

2004
Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:4

    Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Registries; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome

2004
Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome

2004
Severe neurotoxicity caused by gemcitabine treatment.
    Acta oncologica (Stockholm, Sweden), 2004, Volume: 43, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Diseases; Confusion; Deoxycytidine; Female; Gemcitabine; Headache; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Seizures; Urinary Bladder Neoplasms

2004
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
    BMC cancer, 2004, Nov-23, Volume: 4

    Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms

2004
Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
    Gynecologic oncology, 2004, Volume: 95, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis

2004
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Survival Rate

2004
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
    Gynecologic oncology, 2005, Volume: 96, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays

2005
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
    Gynecologic oncology, 2005, Volume: 97, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms

2005
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
    Gene therapy, 2005, Volume: 12, Issue:15

    Topics: Adenocarcinoma; Adenovirus E1A Proteins; Adenoviruses, Human; Animals; Antiviral Agents; Bone Marrow Cells; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genetic Therapy; Liver; Mice; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Virus Replication

2005
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
    Gynecologic oncology, 2006, Volume: 100, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan

2006
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    International journal of oncology, 2006, Volume: 28, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured

2006
Re: "Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival".
    Gynecologic oncology, 2006, Volume: 100, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy

2006
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
    Cancer, 2006, Feb-01, Volume: 106, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carboplatin; Carcinoma; Caspase 2; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Enzyme Activation; Female; Gemcitabine; Humans; Isoflavones; Mice; Ovarian Neoplasms; Paclitaxel; Proteasome Endopeptidase Complex; Transplantation, Heterologous

2006
Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.
    International journal of oncology, 2006, Volume: 28, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Gemcitabine; Glucocorticoids; Humans; Immediate-Early Proteins; Mice; Ovarian Neoplasms; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases

2006
Is thrombotic microangiopathy associated with antitumoral activity?
    Gynecologic oncology, 2006, Volume: 101, Issue:3

    Topics: Acute Kidney Injury; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney; Middle Aged; Ovarian Neoplasms

2006
Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006, Aug-07, Volume: 840, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Monocytes; Ovarian Neoplasms; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2006
Not in the BNF.
    British journal of hospital medicine (London, England : 2005), 2006, Volume: 67, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Emergency Service, Hospital; Fatal Outcome; Female; Fluorouracil; Heart Arrest; Humans; Ovarian Neoplasms; Pharmacopoeias as Topic

2006
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
    Cancer, 2006, Jul-01, Volume: 107, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Taxoids; Tomography Scanners, X-Ray Computed; Treatment Outcome

2006
Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Salvage Therapy; Survival Rate

2006
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
    Cancer, 2006, Aug-01, Volume: 107, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2006
Growth inhibition and apoptosis induction in ovarian cancer cells.
    International journal of oncology, 2006, Volume: 29, Issue:2

    Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genes, p53; Humans; Ovarian Neoplasms; Paclitaxel; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p53

2006
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
    Cancer biology & therapy, 2006, Volume: 5, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; I-kappa B Kinase; Mitosis; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured

2006
[Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer].
    Orvosi hetilap, 2006, Jul-30, Volume: 147, Issue:30

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome

2006
A step in the right direction.
    Nature clinical practice. Oncology, 2006, Volume: 3, Issue:12

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Approval; Endpoint Determination; Female; Gemcitabine; Humans; Neoplasms; Ovarian Neoplasms; Survival Analysis; United States; United States Food and Drug Administration

2006
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
    Investigational new drugs, 2007, Volume: 25, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Ovarian Neoplasms; Respiratory Distress Syndrome; Severity of Illness Index; Taxoids; Tomography, X-Ray Computed; Treatment Outcome

2007
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
    Oncology, 2006, Volume: 71, Issue:1-2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate

2006
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Treatment Outcome

2007
A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
    Archives of gynecology and obstetrics, 2008, Volume: 278, Issue:6

    Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritonitis; Salvage Therapy

2008
Developmental chemotherapy and management of recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Suppl

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2003
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Gynecologic oncology, 2007, Volume: 107, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life

2007
Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma.
    International journal of clinical oncology, 2007, Volume: 12, Issue:5

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms; Treatment Outcome

2007
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adenocarcinoma; Adenoviridae; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Mice; Mice, SCID; Oncolytic Virotherapy; Ovarian Neoplasms; Virus Replication; Xenograft Model Antitumor Assays

2008
Carbon beam therapy in recurrent ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy

2008
[Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2008, Volume: 59, Issue:11

    Topics: Deoxycytidine; Female; Fingers; Gemcitabine; Hand Dermatoses; Humans; Middle Aged; Necrosis; Ovarian Neoplasms; Purpura, Thrombotic Thrombocytopenic; Treatment Outcome

2008
Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
    Cancer investigation, 2008, Volume: 26, Issue:4

    Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity; Single-Blind Method; Treatment Outcome; Tumor Cells, Cultured

2008
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    International journal of clinical oncology, 2008, Volume: 13, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols

2008
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 11

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Base Sequence; Cell Division; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Sequence Data; Nucleoside Deaminases; Ovarian Neoplasms; Phenotype; Ribonucleotide Reductases; RNA, Messenger; Tumor Cells, Cultured; Vincristine

1995
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 11

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Squamous Cell; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms

1995
Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 11

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Drug Tolerance; Female; Fluorometry; Gemcitabine; Head and Neck Neoplasms; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured

1995
Ovarian cancer--new insights into systemic therapy.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:5

    Topics: Antimetabolites, Antineoplastic; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel

1995
Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Cisplatin; Colonic Neoplasms; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Kinetics; Mice; Nucleoside Deaminases; Ovarian Neoplasms; Time Factors; Tumor Cells, Cultured

1994
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Biochemical pharmacology, 1994, Oct-07, Volume: 48, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Mice; Ovarian Neoplasms; Phosphates; Ribonucleotides; Tumor Cells, Cultured

1994
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
    Cancer research, 1994, Aug-01, Volume: 54, Issue:15

    Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; Female; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Sequence Data; Ovarian Neoplasms; RNA, Messenger; Tumor Cells, Cultured

1994
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
    British journal of cancer, 1993, Volume: 68, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured

1993
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    Biochemical pharmacology, 1996, Apr-12, Volume: 51, Issue:7

    Topics: Cytidine Deaminase; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Kinase; Enzyme Inhibitors; Female; Gemcitabine; Humans; Kinetics; Nucleoside Deaminases; Ovarian Neoplasms; Phosphorylation; Tumor Cells, Cultured; Uridine Triphosphate

1996
Activity of gemcitabine in platinum-resistant ovarian germ cell cancer.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Ovarian Neoplasms; Platinum Compounds

1996
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.
    Investigational new drugs, 1996, Volume: 14, Issue:3

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Stem Cell Assay

1996
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
    Cancer, 1997, Jul-15, Volume: 80, Issue:2

    Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Hypoxia; Lung Diseases; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Pulmonary Edema; Respiratory Distress Syndrome

1997
Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:5

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; Microscopy, Electron, Scanning; Ovarian Neoplasms; Protein Kinase C; Tumor Cells, Cultured

1998
Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Clone Cells; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured

1998
Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs.
    International journal of oncology, 1998, Volume: 13, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1998
Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor.
    Anti-cancer drugs, 1998, Volume: 9, Issue:7

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Deoxycytidine; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Ovarian Neoplasms

1998
Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Nucleotides; Ovarian Neoplasms; Tumor Cells, Cultured

1998
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    Biochemical pharmacology, 1999, Feb-15, Volume: 57, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytosine Nucleotides; DNA Damage; Drug Synergism; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured

1999
The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells.
    Oncology research, 1998, Volume: 10, Issue:7

    Topics: Alkaline Phosphatase; Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Isoenzymes; Mitogen-Activated Protein Kinase 1; Ovarian Neoplasms; Protein Kinase C; Subcellular Fractions; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured

1998
The Gynecologic Oncology Group experience in ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Decision Making; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

1999
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    British journal of cancer, 1999, Volume: 80, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorometry; Gemcitabine; Humans; Intracellular Fluid; Lung Neoplasms; Mice; Ovarian Neoplasms; Platinum; RNA; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay

1999
Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
    American journal of clinical oncology, 1999, Volume: 22, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; United States

1999
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    Biochimica et biophysica acta, 2000, Mar-06, Volume: 1474, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Leukemia; Lung Neoplasms; Mice; Ovarian Neoplasms; Rats; Ribonucleotide Reductases; Ribonucleotides; Tumor Cells, Cultured

2000
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
    Anti-cancer drugs, 1999, Volume: 10, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms

1999
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:15

    Topics: Antineoplastic Agents, Phytogenic; Cell Division; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured

2000
The role of laparoscopy in second-look evaluations for ovarian cancer.
    Gynecologic oncology, 2001, Volume: 80, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Laparoscopy; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Reoperation; Retrospective Studies

2001
The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.
    Anti-cancer drugs, 2000, Volume: 11, Issue:10

    Topics: Adenosine Triphosphate; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tumor Cells, Cultured

2000
Cell cycle effects of gemcitabine.
    International journal of cancer, 2001, Aug-01, Volume: 93, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Survival; Deoxycytidine; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; S Phase; Tumor Cells, Cultured

2001
Gemcitabine in the treatment of ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2001, Volume: 11 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome

2001
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
    Gynecologic oncology, 2001, Volume: 82, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide

2001
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome

2001
Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells.
    Oncology research, 2000, Volume: 12, Issue:9-10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Time Factors; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1

2000
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
    Anti-cancer drugs, 2002, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Treatment Failure

2002
Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
    International journal of cancer, 2002, May-20, Volume: 99, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cytosol; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovary; Oxidoreductases; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Time Factors

2002
Recurrent ovarian cancer as chronic disease.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Deoxycytidine; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Recurrence; Topotecan; Trastuzumab

2002
Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
    Biochemical and biophysical research communications, 1992, Apr-30, Volume: 184, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; IMP Dehydrogenase; Kinetics; Leukemia, Promyelocytic, Acute; Liver Neoplasms, Experimental; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Ribavirin; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Stem Cell Assay

1992
Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
    Gynecologic oncology, 1992, Volume: 45, Issue:1

    Topics: Antimetabolites, Antineoplastic; Blotting, Western; Bone Marrow Cells; Cisplatin; Cystadenocarcinoma; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Glutathione Transferase; Humans; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; RNA, Messenger; Stem Cells; Tumor Cells, Cultured

1992
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Squamous Cell; Cell Division; Cell Line; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kinetics; Mice; Ovarian Neoplasms

1991
chemdatabank.com